Oxurion NV (XBRU:OXUR) Momentum Rank : 0 (As of Jun. 06, 2024)

View and export this data going back to 2006. Start your Free Trial

What is Oxurion NV Momentum Rank?

Oxurion NV has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Oxurion NV Momentum Rank Related Terms

Thank you for viewing the detailed overview of Oxurion NV's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Oxurion NV (XBRU:OXUR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxurion NV (XBRU:OXUR) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

TG4:Germany

Address

Gaston Geenslaan 1, Leuven, BEL, B-3001

Website

https://www.oxurion.com

Oxurion NV is a clinical stage biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME). The Group's research and development facilities are located in Belgium .The Company is engaged in the development of drugs to treat back-of-the-eye diseases, more specifically, ophthalmologic pharmaceuticals to treat vascular retinal disorders, specifically DME.

Oxurion NV (XBRU:OXUR) Headlines

No Headlines